Towards Healthcare
Respiratory Drugs Market Size Envisioned at USD 28.11 Billion by 2032

Respiratory Drugs Market Size Envisioned at USD 28.11 Billion by 2032

Status: Published Category: Therapeutic Area Insight Code: 5137 Format: PDF / PPT / Excel

The respiratory drugs market size is estimated to grow from 16.57 billion in 2023 to reach around USD 28.11 billion by 2032, registering a CAGR of 5.8% between 2024 and 2032.

Respiratory Drugs Market Size 2023 - 2032

Unlock Infinite Advantages: Subscribe to Annual Membership

Report Highlights

  • Chronic Obstructive Pulmonary Disease (COPD) being the most prevalent respiratory disorder captured the largest 36% market share in 2023.
  • Bronchodilators recorded a dominant 40% market share in 2023.
  • Hospital pharmacies were the top distributors among all in 2023.

In 2021, the CDC reported 142,342 deaths from lower chronic respiratory disease in the United States, highlighting the urgent need for innovative treatment approaches. This significant toll underscores the demand for advancements in managing these conditions effectively.

Respiratory disorders cover a broad range of issues affecting the system responsible for breathing, including the lungs, airways, and respiratory muscles. When these parts of the body encounter problems, it can make breathing difficult and lead to various symptoms like coughing, wheezing, shortness of breath, and chest tightness. There are several respiratory disorders, each with its characteristics and causes. Obstructive disorders, such as asthma and chronic obstructive pulmonary disease (COPD), involve blockages in the airways, hindering airflow in and out of the lungs. Restrictive disorders, like pulmonary fibrosis, limit the lungs' ability to expand fully, making breathing hard.

  • In 2020, the National Institutes of Health undertook a comprehensive investigation involving 255,857 patients to examine the effectiveness of inhaled treatments, including triple therapy, for Chronic Obstructive Pulmonary Disease (COPD).

Child and Adult Asthma Prevalance By Age and Sex in U.S. 2021

As more people are found to have respiratory disorders, there's a growing demand for treatments that can ease symptoms and enhance life quality. Effective treatments can reduce symptoms, prevent complications, and support active lifestyles despite the condition. According to the CDC, diabetes mellitus was the most common medical risk factor for TB illness in 2021 (23.9%), while 4.2% of TB patients were also diagnosed with HIV. Additionally, advancements in medical research are leading to new treatments like bronchodilators and corticosteroids for symptom relief, targeted therapies for lung cancer and pulmonary rehabilitation programs to boost lung function and overall health.

Infections caused by viruses, bacteria, fungi, or other pathogens can also affect the respiratory system, leading to illnesses like the common cold, influenza, pneumonia, tuberculosis, and respiratory syncytial virus (RSV) infection. Inflammatory disorders, including bronchitis and allergic rhinitis, involve airways or lung tissue inflammation, resulting in breathing difficulties and discomfort. Neoplastic disorders, like lung cancer, involve abnormal cell growth in the respiratory system, which can lead to serious health complications.

Respiratory disorders can stem from various factors, including genetic predisposition, environmental factors like pollution and exposure to tobacco smoke, infections, lifestyle choices such as smoking and poor nutrition, and occupational exposures to dust, chemicals, or fumes. It's crucial to address these underlying causes to manage respiratory conditions effectively.

  • In February 2021, Royal Philips N.V. finalized its acquisition of BioTelemetry, Inc., which will enhance its cancer diagnostics segment.

Appropriate treatment is essential for managing respiratory disorders and improving patients' quality of life. Treatment aims to alleviate symptoms, slow disease progression, prevent complications, improve lung function, and enhance long-term outcomes. This may involve medication such as bronchodilators, corticosteroids, antibiotics, lifestyle modifications, oxygen therapy, and other interventions tailored to the individual's needs.

Respiratory disorders can significantly impact daily life, but understanding their types, causes, and the importance of appropriate treatment is critical to managing these conditions effectively. Early diagnosis, lifestyle changes, and medical interventions are crucial in optimizing respiratory health and well-being.

The Impact of Smoking Tobacco Leading to Breathing Problems

In high-income countries, tobacco smoking is responsible for more than 70% of COPD cases. In contrast, in low- and middle-income countries (LMICs), tobacco smoking contributes to 30–40% of COPD cases, with household air pollution being a significant risk factor.

Tobacco smoking is a significant contributor to respiratory disorders like COPD, lung cancer, and respiratory infections. When people smoke, they inhale harmful substances into their lungs, causing damage over time. COPD, which includes conditions like chronic bronchitis and emphysema, is ubiquitous among smokers because tobacco smoke irritates and inflames the airways, making it hard to breathe. Lung cancer, another severe consequence of smoking, occurs when these harmful substances cause abnormal cell growth in the lungs.

  • According to the World Health Organization (WHO), lung cancer led to 1.8 million deaths worldwide in 2020. These alarming figures have prompted an emphasis on early disease detection, fueling market growth. Advancements in imaging technologies for diagnosing lung cancer have significantly enhanced.

Smoking makes the body's defense system weaker, so smokers can quickly get respiratory infections like pneumonia and bronchitis. The harmful substances in tobacco smoke can also stop the tiny hairs in our airways from working correctly. These hairs usually help clean out mucus and dirt, but when they're paralyzed by smoke, mucus can build up and cause more infections. Efforts to reduce smoking rates and address smoking-related respiratory diseases are crucial for public health. Smoking cessation programs, which help people quit smoking, are an essential part of these efforts. These programs may include counseling, support groups, and medications to help manage nicotine withdrawal symptoms. Additionally, treatments for tobacco-related conditions focus on managing symptoms, slowing disease progression, and improving overall lung health.

By reducing smoking rates and providing support for those affected by smoking-related respiratory diseases, we can significantly improve public health outcomes. Prevention and early intervention are vital in reducing the burden of respiratory disorders associated with tobacco smoking, ultimately leading to healthier communities and improved quality of life for individuals affected by these conditions.

Corticosteroids Act as Powerful Defenders For Our Lungs

Corticosteroids are very good at fighting inflammation, a big problem in respiratory disorders like asthma, COPD, and allergies. These medications help calm down the swelling and irritation in our airways and lungs, making breathing easier and reducing symptoms like coughing and wheezing.

For instance,

  • In 2020, about 1 million individuals visited the emergency room for asthma care, with roughly 94,560 requiring hospital admission due to the condition. This significant prevalence of pulmonary diseases underscores the importance of effective treatment. Corticosteroids are frequently recommended for pulmonary conditions to address their widespread occurrence. 

For people with asthma, corticosteroids are often given as inhalers or pills to keep the airways from getting too swollen and tight. Using these regularly can prevent asthma attacks and make breathing smoother, especially for those with severe symptoms.

In COPD, corticosteroids also help soothe inflammation in the airways, improving lung function and making breathing easier. They're usually used for short periods during flare-ups to get symptoms under control. And for those with allergies causing stuffy noses and sneezing, corticosteroid nasal sprays work wonders. They calm down the inflammation in the nose, reducing congestion and making breathing easier.

Combinational Therapies

Sr. No. Combination Therapy Indication
1. ICS with Long-Acting Muscarinic Antagonists (LAMA) This combination is frequently prescribed for chronic obstructive pulmonary disease (COPD), targeting various aspects of airway relaxation compared to ICS/LABA. Examples include Trivento (fluticasone/umeclidinium/vilanterol) and Breztri Aerosphere (beclomethasone/glycopyrrolate/formoterol).
2. Systemic Corticosteroids These medications are commonly employed for short-term management of severe exacerbations in different pulmonary conditions like asthma and COPD. While they help reduce inflammation, they may have more side effects compared to inhaled corticosteroids.
3. Triple Therapy Combining ICS, LABA, and LAMA is occasionally prescribed for patients with severe or inadequately managed COPD, as it addresses several disease mechanisms simultaneously.

Now, why are corticosteroids becoming more popular in treating respiratory problems? These conditions are becoming more common, and corticosteroids are really good at helping people feel better. Additionally, new and improved versions of these medications are being made, making them easier to use and safer for long-term use.

But, doctors need to be careful when prescribing corticosteroids because they can have side effects, especially with long-term use. So, while corticosteroids are excellent at helping us breathe better, doctors need to find the right balance to ensure we get all the benefits without any unwanted side effects.

Expenses Can Pose a Significant Challenge

The cost of treating respiratory disorders like asthma and COPD can be high. This includes the price of medications, inhalers, breathing devices, and visits to the doctor or hospital. For people who don't have good insurance or a lot of money, these costs can be a big problem. It might mean they can't afford the necessary care or buy their medications regularly.

  • According to the Forum of International Respiratory Societies, the significant prevalence and severity of the illness result in a substantial economic burden. Treating Chronic Obstructive Pulmonary Disease (COPD) alone accounts for approximately 6% of total healthcare expenditure (€38.6 billion annually) in the European Union, representing over half (56%) of all expenses for respiratory disease treatment.

This can lead to severe consequences because, without proper treatment, respiratory conditions can get worse and cause more health problems. People might end up having more frequent and severe asthma attacks or COPD flare-ups, which can be scary and even life-threatening.

High treatment costs can also affect how well people stick to their treatment plans. If they can't afford their medications or doctor visits, they might skip doses or delay seeking medical help when they're not feeling well. This can make it harder to control their symptoms and manage their condition effectively.

To address this issue, healthcare systems need to find ways to make treatments more affordable and accessible for everyone. This might involve providing financial assistance programs, lowering medication costs, or offering free or discounted healthcare services for those in need. By making treatments more affordable, we can ensure everyone can access the care they need to stay healthy and manage their respiratory disorders effectively.

Geographical Landscape

In North America, the landscape for treating respiratory disorders like asthma and COPD is shaped by several factors.

  • In 2021, According to the CDC, the United States recorded 142,342 deaths from lower chronic respiratory disease.

One big thing is that there are a lot of people here who have these conditions. This means there's a high demand for treatments to help them breathe better and feel more comfortable. There are also many healthcare facilities, doctors, and specialists who specialize in treating respiratory disorders. This is good because it means people can access the necessary care to manage their condition, such as medications, inhalers, and breathing tests. Accessing healthcare can still be challenging for some people, especially those who live in rural areas or don't have good insurance. This can make it harder for them to get the care they need and afford their medications.

Number of Adults with COPD in America (in Millions), 2022

The Asia Pacific region encompasses a wide range of healthcare systems, ranging from highly developed healthcare systems to respiratory disorders such as asthma, COPD, and respiratory infections, which significantly burden public health in the Asia Pacific region. Factors such as air pollution, tobacco smoking, and indoor biomass fuel use contribute to the high prevalence of respiratory diseases in many countries. Disparities in access to healthcare services exist within and between countries in the Asia Pacific region. Rural and remote communities often face challenges accessing specialized respiratory care, diagnostic facilities, and essential medications. Improving healthcare infrastructure and expanding access to respiratory services are critical for addressing these disparities.

Competitive Landscape

Different companies and healthcare providers are working to offer the best treatments for respiratory problems in the competitive landscape of the respiratory drug market. Like in a race, these companies compete to develop and sell medications, devices, and services that help people breathe better and manage their respiratory conditions. Some companies focus on making inhalers or pills that reduce lung inflammation, making breathing more accessible for people with asthma or COPD. Others might specialize in developing new technologies, like advanced breathing devices or smart inhalers, to help patients better manage their symptoms. Healthcare providers, like hospitals and clinics, also play a significant role in this competitive landscape. They might offer specialized respiratory care services, such as lung function tests or pulmonary rehabilitation programs, to help patients improve their lung health and manage their conditions more effectively.

Market Player Respiratory Product Name Global Sales in 2021 (USD Million)
GSK Plc Nucala (mepolizumab) 1293.2
Novartis AG Xolair XX
AstraZeneca Symbicort XX
AstraZeneca Fasenra XX

Recent Developments

  • In August 2022, a trial was conducted to evaluate the potential of vamorolone as a treatment for Becker muscular dystrophy (BMD). The initial participant received a dose of nandrolone as part of this investigation conducted by ReveraGen BioPharma. The study aims to determine if this steroid medication could serve as a treatment for various forms of muscular dystrophy.
  • In 2021, Konica Minolta, Inc., in partnership with Seki Aoi Techno Co., Ltd., expanded their pulse oximeter manufacturing capacity by over 20-fold.
  • In March 2020, the Food and Drug Administration (FDA) granted Abbott emergency use authorization (EUA) for the Abbott ID NOW COVID-19 test. This molecular point-of-care test is designed to detect COVID-19 in under 5 minutes and operates on the Abbott ID NOW platform.

Respiratory Drugs Market Players

  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Mylan Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Ltd.

Respiratory Drugs Market Segment

By Disease Type

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer
  • Respiratory Tract Infection
  • Allergic Rhinitis
  • Cystic Fibrosis (CF)
  • Others

By Drug Class

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Antibiotics
  • Target Therapy
  • Immunotherapy
  • CFTR
  • Others

By Route of Administration

  • Oral
  • Nasal
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Namrata Bukshet is not just a market researcher; she is a detective, a storyteller, and a champion for healthier lives. Her journey began with a Bachelor of Pharmacy degree and a thirst for knowledge that led her to pursue a Post Graduate Diploma in Pharmaceutical Management. Her curiosity for consumer behaviour and market trends burned bright. She delved deep into the world of lifestyle disorders, conducting extensive research that sheds light on the intricate dance between personal choices and societal pressures. This exploration culminated in a groundbreaking paper on E-Biz: Indias 1st G2B Online Portal, presented at an international conference, where her insights resonated with a global audience. But Namrata has impact extends far beyond a single paper. Her expertise has shaped the very landscape of market research and pharmaceuticals. Her keen eye for detail and unwavering commitment to understanding the why behind consumer behaviour have made her a sought-after professional in the industry. She is the decoder ring that unlocks the secrets hidden within data, the translator who turns complex trends into actionable insights. As she continues to unravel the mysteries of consumer behaviour, she paves the way for a future where healthcare is not just about treatment but about understanding the why and building a bridge to a healthier world, one insightful discovery at a time.


Respiratory disorders affect the lungs, airways, and respiratory muscles, leading to coughing, wheezing, shortness of breath, and chest tightness.

Corticosteroids are crucial in managing respiratory disorders due to their anti-inflammatory properties, which help reduce inflammation in the airways and lungs. By alleviating inflammation, corticosteroids can improve lung function, relieve symptoms like coughing and wheezing, and prevent exacerbations in conditions like asthma and COPD, leading to better overall respiratory health.

One of the hurdles in the respiratory drugs market is the high cost of medications, devices, and healthcare services, which can limit access to care for individuals without adequate insurance coverage or financial resources.

Centers for Disease Control and Prevention, National Institute of Health, World Health Organization, National Cancer Institute,, Forum of International Respiratory Societies.